Novartis报告Q4销售额强劲,超过预期,预测2025年增长强劲。 Novartis reports strong Q4 sales, exceeding expectations, and forecasts robust growth for 2025.

一家大制药公司Novartis报告第四季度销售额132亿美元,按固定货币计算增长16%,超过了分析家的预期。 Novartis, a major pharmaceutical company, reported fourth-quarter sales of $13.2 billion, a 16% increase on a constant currency basis, surpassing analysts' expectations. Entresto和Comestyx等关键药物是增长的动力。 Key drugs like Entresto and Cosentyx drove the growth. Novartis虽然没有达到全年销售指导,但认为2025年的前景十分光明,预测“中位数到高位数”的销售增长,核心业务收入增长“高位数到低位数”。 Despite falling short of its full-year sales guidance, Novartis sees strong prospects for 2025, forecasting sales growth of "mid- to high single digits" and core operating income increase of "high single to low double-digits." 该公司计划通过收购加强其发展管道。 The company plans to boost its development pipeline through acquisitions.